AFFLUENT MEDICAL Affluent Medical : Financial communication schedule for the second half of 2021
Transparency directive : regulatory news
|
Affluent Medical PRESS RELEASE Aix-en-Provence, 13 July 2021 - 17.45 p.m.
Financial communication schedule for the second half of 2021
Affluent Medical (code ISIN: FR0013333077 - Ticker: AFME), a French medtech specialising in the international development and industrial scale-up of innovative medical prostheses, at a clinical stage, to treat urinary incontinence and cardiac mitral valve pathology, today announces the date of publication of its 2021 half year results (audited) and its participation in two broker forums:
About Affluent Medical Affluent Medical is a French MedTech company founded by Truffle Capital with the ambition to become a world leader in the treatment of heart and vascular diseases, which are the world's leading cause of death, and of urinary incontinence, which today affects one in four adults. Affluent Medical develops innovative, next-generation minimally invasive implants to restore key physiological functions in these areas. The company's four major technologies are currently in preclinical and clinical phases. A first medical device is expected to be launched by 2023 with Kalios in Europe. For more information: www.affluentmedical.com
Contacts :
Regulatory filing PDF file File: Financial communication schedule for the second half of 2021 |
| Language: | English |
| Company: | Affluent Medical |
| 320 avenue Archimède, Les pléiades III Bâtiment B | |
| 13100 Aix en Provence France | |
| France | |
| Phone: | +33 4 42 95 12 20 |
| E-mail: | jerome.geoffroy@affluentmedical.com |
| Internet: | https://www.affluentmedical.com/ |
| ISIN: | FR0013333077 |
| Euronext Ticker: | AFME |
| AMF Category: | Inside information / Issuer activities (acquisitions, sales...) |
| EQS News ID: | 1218475 |
| End of Announcement | EQS News Service |
1218475 13-Jul-2021 CET/CEST